MT-201 / CREATE Medicines, Duke University - LARVOL DELTA

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States (ASH 2024) - "Published recommendations for screening/prevention of late complications have been available (Majhail, BBMT 2012); however, their utilization by clinicians practicing at U.S. transplant centers (TC) is unknown...Conclusion : This is the first report of clinician adherence to recommended screening/preventive guidelines for HCT survivors across 19 TC in the U.S. Less than half of pts were screened for bone density and diabetes while higher adherence to lipid, thyroid, kidney function, and oral health was observed. Several factors were associated with adherence, and these findings will guide the development of interventions to improve clinician adherence to screening/preventive practice guidelines."

Adherence • Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Diabetes • Graft versus Host Disease • Hematological Malignancies • Metabolic Disorders • Oncology • Transplantation

DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Michael Gunn | N=27 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • GZMB • IFNG • MGMT

Contemporary Comparison of Alternative Donor Transplantation Sources for Pediatric Hemophagocytic Lymphohistiocytosis Demonstrates Effective Outcomes for Umbilical Cord Blood Grafts: A Single Center Experience (TCT-ASTCT-CIBMTR 2023) - "Myeloablative conditioning regimens included targeted busulfan combined with fludarabine (Flu) +/- cyclophosphamide & +/- anti-thymocyte globulin (n = 2 MUD, n = 1 UCB). Reduced toxicity regimens included Flu + melphalan + alemtuzumab +/- thiotepa & +/- hydroxyurea (n= 2 MUD, n = 4 UCB) [Patel et al, BBMT 2017]. Graft versus host disease (GvHD) prophylaxis was calcineurin inhibitor (CNI) + mycophenolate mofetil (n = 2 MUD, n = 5 UCB), or + methotrexate (n = 1 MUD), or + methylprednisolone (n = 1 MUD)... Our single-institution experience demonstrates feasibility and excellent, durable outcomes with tolerable toxicity using partial HLA-matched UCB HSCT and reduced toxicity conditioning. Further exploration of UCB compared with other readily available alternative donor sources, e.g. haploidentical related donors, in larger prospective studies is warranted to improve pediatric HLH outcomes."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics • Rare Diseases • Respiratory Diseases • Transplantation

DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Michael Gunn | Trial completion date: Aug 2025 ➔ Nov 2025

Trial completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • GZMB • IFNG • MGMT

DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Michael Gunn | Trial completion date: Mar 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2022 ➔ Feb 2025

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • GZMB • IFNG • MGMT